SNWV - SANUWAVE Health, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1750
+0.0050 (+2.94%)
At close: 3:11PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.1700
Open0.1680
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1650 - 0.1780
52 Week Range0.1000 - 0.3300
Volume301,396
Avg. Volume338,860
Market Cap34.281M
Beta (3Y Monthly)-1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.0490
Earnings DateNov 18, 2019 - Nov 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SANUWAVE Health to Hold Third Quarter 2019 Financial Results and Business Update Call on Friday, November 15, 2019

    SUWANEE, GA, Nov. 12, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) announced today that the Company will release financial results for the third quarter.

  • GlobeNewswire

    SANUWAVE Signs Agreement for dermaPACE® System Joint Venture in Brazil

    SUWANEE, GA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) is pleased to announce that it has signed a term sheet for a Brazilian joint venture for the dermaPACE® System with IDIC Group of São Paulo, Brazil. The companies will share profits equally in the wound care arena with the dermaPACE® System as the center piece of the Brazilian joint venture’s product portfolio. SANUWAVE will receive $600,000 from IDIC Group for the exclusive territorial rights for the dermaPACE® System in Brazil.

  • GlobeNewswire

    SANUWAVE Successfully Completes Extensive Round of Quality System and Technical File Audits

    SUWANEE, GA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating shockwave systems for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s key to success is its pursuit of Quality. The company is very pleased to announce that an extensive round of Quality System audits by multi-national organizations have been successfully completed.

  • GlobeNewswire

    SANUWAVE® Launches Partnership in Oman

    SUWANEE, GA, Oct. 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced their attendance and sponsorship in the Global Diabetic Foot Course (“GDFC”) in Muscat, Oman taking place November 7-10, 2019 through our partners in the region, Taiba Healthcare and MenaCare. GDFC is a premier interdisciplinary diabetic foot four day course taking place November 7-10, 2019 in Muscat, Oman.

  • GlobeNewswire

    SANUWAVE Continues to Increase Clinical Symposia Presence With SAWC Fall 2019

    Symposia and Posters Presenting Compelling Clinical Evidence in Treating Diabetic Foot Ulcers With dermaPACE®System SUWANEE, GA, Oct. 16, 2019 -- via NEWMEDIAWIRE.

  • GlobeNewswire

    SANUWAVE Increases Clinical Symposia Presence With Three Posters at Wounds Canada

    Studies Show Significant Improvements When dermaPACE® System Was Used in the Treatment of Chronic Wounds SUWANEE, GA, Oct. 10, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health,.

  • GlobeNewswire

    SANUWAVE to Attend a Total of Eight Medical Conferences in the Fourth Quarter of 2019 Supported by Symposiums, Posters, and KOLs

    SUWANEE, GA, Sept. 13, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV), an emerging medical technology company focused on the development and commercialization.

  • SNWV: NGS Reimbursement Update Should Catalyze U.S. Adoption, Procedure Revenue
    Zacks Small Cap Research

    SNWV: NGS Reimbursement Update Should Catalyze U.S. Adoption, Procedure Revenue

    By Brian Marckx, CFA OTC:SNWV READ THE FULL SNWV RESEARCH REPORT Q2 Results, Operational Update : Record U.S. Product Sales. NGS Update Should Help Drive Adoption, Procedure Revenue …. SANUWAVE (OTC:SNWV) reported financial results for their second quarter ending June 30th and provided a business update. As it relates to the financials, while revenue

  • Insiders Roundup: Facebook, Community Health Systems
    GuruFocus.com

    Insiders Roundup: Facebook, Community Health Systems

    Largest insider buys Continue reading...

  • GlobeNewswire

    SANUWAVE Health Reports Second Quarter 2019 Financial Results

    SUWANEE, Ga., Aug. 15, 2019 -- SANUWAVE Health, Inc. (OTCQB: SNWV) reported financial results for the three months ended June 30, 2019 with the SEC on Wednesday, August 14,.

  • GlobeNewswire

    SANUWAVE Accelerates Claims Coverage Expansion One Year Ahead of Expectations Due to Recent Positive Change in Reimbursement Coverage

    SUWANEE, GA, Aug. 14, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) an emerging medical technology company focused on the development and commercialization of.

  • GlobeNewswire

    SANUWAVE to Hold Second Quarter 2019 Financial Results and Business Update Call on Thursday, August 15, 2019

    SUWANEE, GA, Aug. 13, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) announced today that the Company will release financial results for the second quarter.

  • GlobeNewswire

    SANUWAVE Announces New Issue of “The Pulse” Newsletter, Summer 2019

    Kevin Richardson, Chairman and CEO, further shared that, “In 2019, our focus with the newsletter, The Pulse, continues to be on informing interested parties about our contributions towards advancing wound care and the use of shockwave technology.  In the spirit of this approach, SANUWAVE aims to update its subscriber list quarterly with an exciting recap. The goal of The Pulse is to allow a medium to inform customers, patients, partners, and the public about the various initiatives underway at SANUWAVE.  If you would like to subscribe to The Pulse, please email us at thepulse@sanuwave.com.

  • GlobeNewswire

    SANUWAVE Increases Clinical Symposia Presence With Recent Abstracts and Posters: Clinical Results Using the dermaPACE System in the Treatment of Chronic Wounds and orthoPACE System in Basic Orthopedic Research

    In addition to forward looking plans for pharma-economic studies involving the dermaPACE System, on-going case series measuring the increase in perfusion after treatment with dermaPACE is on-going at three major universities.  A comprehensive evaluation of the effects on wound response to shock count and wound area is on-going in Poland.  In the past few months, a number of posters have been presented at major wound care symposia and research forums. ·    Dr. Windy Cole, DPM, Adjunct Professor and Director of Wound Care KSUCPM and Medical Director, UH Ahuja Wound Center presented at “The National”, the annual gathering for American Podiatric Medical Association (APMA) held in Salt Lake City, Utah in July 2019 titled: “The Use of Non-Invasive Pulsed Acoustic Cellular Expression System to Promote Angiogenesis in Chronic Wounds.”  This case series discussed results to date of the objective to measure and monitor tissue oxygen saturation levels before and after a treatment regimen using the dermaPACE System on DFUs.  Measurement of hemoglobin levels is via the Snapshot NIRS device from Kent Imaging.

  • GlobeNewswire

    SANUWAVE Exhibiting at the APMA 2019 Annual Scientific Meeting in Salt Lake City, Utah July 11-14, 2019

    SUWANEE, GA, July 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) is pleased to announce that the company will exhibit at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, also known as “The National”, in Salt Lake City, Utah on July 11 – 14, 2019.  SANUWAVE is excited to showcase their wound care device system, dermaPACE®, to attending podiatrists, physician assistants and other professionals. This will be the first time SANUWAVE will be exhibiting at APMA since the dermaPACE® System received FDA clearance in December 2017.  The company will be exhibiting in Booth 520.

  • GlobeNewswire

    SANUWAVE President, Shri Parikh, Receives Top 100 Healthcare Leaders Award

    Suwanee, GA, June 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, is proud to announce that Shri Parikh, President of its Healthcare Division, was presented with the “Top 100 Healthcare Leaders” award at the International Forum on Advancements in Healthcare (IFAH) Conference at Caesar’s Palace in Las Vegas. The International Forum on Advancements in Healthcare (IFAH) is dedicated to the mission of improving healthcare by facilitating an open dialogue between different industry stakeholders.

  • GlobeNewswire

    SANUWAVE Announces Second Peer Review Article Published on Treatment of Diabetic Foot Ulcers

    Suwanee, GA, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announces the follow-on publication of the research that investigated the effects of dermaPACE® extracorporeal shock wave technology (ESWT) compared with Standard of Care in the treatment of diabetic foot ulcers. The peer reviewed article, titled “Focused shockwave therapy in diabetic foot ulcers: secondary endpoints of two multicentre randomized controlled trials” by Robert Galiano M.D, Robert Snyder, DPM, Perry Mayer MB, Oscar Alvarez PhD, Lee C. Rogers DPM has been published in the June 2019 issue of the Journal of Wound Care.  This is the second peer reviewed article detailing the results of Phase III DFU trials using dermaPACE as the investigative device and is a follow-on to the first peer-reviewed article “Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre, prospective, controlled, double-blinded, randomised phase III clinical trials” by the same authors.

  • Zacks Small Cap Research

    SNWV U.S. Roll-Out Strategy Coming Together, Placement Guidance Raised 10% to 110 Units

    Q1 Results, Operational Update: International Sales Disappoint But U.S. Strategy Coming Together. SANUWAVE (SNWV) reported financial results for their first quarter ending March 31st and provided a business update. Recognition of licensing fees, related to upfront and subsequent payments under recently-penned joint venture and OUS distribution agreements, has helped buoy international sales.

  • GlobeNewswire

    Sanuwave Health Reports First Quarter 2019 Financial Results

    SUWANEE, Ga., May 21, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB:  SNWV) reported financial results for the three months ended March 31, 2019 with the SEC on.

  • GlobeNewswire

    SANUWAVE Health Engages Alira Health to Explore Strategic Alternatives and Partnerships in the European Wound Market

    Suwanee, GA, May 20, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV),  an emerging medical technology company focused on the development and commercialization.

  • GlobeNewswire

    SANUWAVE Health to Hold First Quarter 2019 Financial Results and Business Update Call on Tuesday, May 21, 2019

    SUWANEE, GA, May 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the first quarter ended March 31, 2019 next week. The Company will also host a conference call on Tuesday, May 21, 2019, beginning at 9AM Eastern Time to discuss the first quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (SNWV) (www.SANUWAVE.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

  • GlobeNewswire

    SANUWAVE Health Comments on Recent News and Investor Relations Promotional Activity

    Suwanee, GA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today commented on the Company’s promotional activities. This has included an increase in social media activity on sites such as LinkedIn, Facebook and Twitter.  In late March, the Company also released its own newsletter, The Pulse reaches 3,000 contacts, mainly in the healthcare field.

  • GlobeNewswire

    SANUWAVE Health Enters the Carolinas, Hires Key Representative and Will Participate in the Modern Wound Care Management Conference April 26-27 in Greensboro, NC

    Suwanee, GA, April 23, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) ( www.sanuwave.com) announced they have entered North and South Carolina as their 5th and.

  • ACCESSWIRE

    Sanuwave Health to Present at the Planet MicroCap Showcase 2019 on May 1 in Las Vegas, NV

    SUWANEE, GA / ACCESSWIRE / April 22, 2019 / SANUWAVE Health, Inc. (OTCQB: SNWV) ( www.sanuwave.com ) SANUWAVE Health, Inc. is an emerging regenerative medicine company focused on the development and commercialization ...

  • GlobeNewswire

    SANUWAVE Provides an Update on International Registrations Received, Attendance at Trade Shows and ISO Certification

    SUWANEE, GA, April 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) is pleased to provide an update regarding the Company’s regulatory status in the worldwide sales and distribution of the company’s medical devices.  In addition to our long-standing presence in Europe, Canada, and South Korea, SANUWAVE® has been extremely active adding major and emerging medical device markets to our portfolio. In addition to countries in which SANUWAVE is making its presence known, we expect to expand this list with 3 – 4 more registrations in 2019.  We are actively engaged in the registration and licensing process in Asia with Indonesia, Singapore, and Taiwan (for dermaPACE®).  Closer to home, SANUWAVE is working on licensing in Mexico, Costa Rica, Panama, and Brazil.  These processes are time-consuming, and we are anticipating successful completion to most, but not all, of these market applications.